chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Injection site swelling, appears red and itchy with about 3 inches in size; Appears itchy; Small red spot at the injection site; Tingling sensation on her skin, legs and back; arm soreness; A spontaneous report was received from an other health care professional, concerning herself, a 31-years-old female patient, who received Moderna's COVID-19 Vaccine and developed tingling sensation on her skin, legs and back; arm soreness;  small red spot at the injection site and injection site swelling, appears red and itchy with about 3 inches in size.  The patient's medical history was not provided. Concomitant medications reported included ethinylestradiol, levonorgestrel; ascorbic acid, chromium, copper, folic acid, inositol, magnesium, manganese, nicotinamide, pantothenic acid, potassium, pyridoxine hydrochloride, retinol, riboflavin, selenium, vitamin b1 nos, vitamin b12 nos, vitamin e nos, zinc; fish oil 1000 mg and sumatriptan as needed.   On 31-Dec-2020, prior to the onset of events, the patient received their first of two planned doses of mRNA-1273 (lot number 039K20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection.   On 31-Dec-2020, minutes after the administration of vaccine. the patient developed tingling sensation on her skin, legs and back that had lasted for 30 minutes and also developed arm soreness which had lasts for 2-3 days. Additionally, on 08-Jan-2021, a small red spot was evident at the injection site and on 09-Jan-2021 she also noticed that it was swelled up, appears red and itchy with about 3 inches in size. Treatment for the event included over the counter (OTC) diphenhydramine 25 mg, q4-6hrs (2 tablets last night). Patient also reported that she was planning to take just 1 tablet and apply OTC itch cream.  Action taken with mRNA-1273 in response to the events were not provided.   The events, tingling sensation on her skin, legs and back were considered resolved or on 31-Dec-2020. The event, arm soreness was considered resolved on 02-Jan-2021. The outcome of the events, small red spot at the injection site and injection site swelling, appears red and itchy with about 3 inches in size was not reported.; Reporter's Comments: This spontaneous report concerns 31-years-old female patient who experienced events of tingling sensation on her skin, legs and back; arm soreness; small red spot at the injection site and injection site swelling, appears red and itchy with about 3 inches in size. The events occurred on the same day after the administration of the first dose of the mRNA-1273 vaccine (Lot #: 039K20A, expiration date-unknown).  Treatment included diphenhydramine (OTC). Outcome is resolved for tingling sensation and unknown for other events. Based on the information provided, which includes a temporal association between the reported events and the administration of mRNA-1273 vaccine, a causal association cannot be excluded. The events of ; small red spot at the injection site and injection site swelling, appears red and itchy are consistent with the known safety profile of mRNA-1273 vaccine.
TESTED POS 01/19/2022 07:15pm Tested because of Sore throat. I started Dayquil/Nyquil and Advil. I also used Flonase. I did virtual visit with a provider. High dose of Zinc and Vitamin C.
Redness and swelling at site of injection. 10 days post injection ring was in excess of 25 mm (in excess of a quarter size). 2 weeks post injection in same arm of injection (left arm) child developed a rash. Culture was ordered by Dr at clinc. Verified by culture as "rare" staph infection.
sleepiness; nausea; chills; night sweats; muscle aches/ increased muscle aches; mild headache/ moderate headache; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A female patient (not pregnant) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), administered in arm right, administration date 25Mar2021 13:00 (Batch/Lot number: unknown) as dose 2, single for COVID-19 immunization. Relevant medical history included: "Asthma" (unspecified if ongoing); "Autoimmune disorder" (unspecified if ongoing); "known allergy to iodine intravenous (IV) contrast" (unspecified if ongoing); "known allergy to bee stings" (unspecified if ongoing). Concomitant medication included: fluticasone propionate, salmeterol xinafoate (ADVAIR, strength: 250/50, units not provided). Vaccination history included: BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE (dose 1, single; Batch/Lot number: unknown, vaccine location: left arm), administration date/time: 25Feb2021 at 01:00 PM, for COVID-19 immunization. The following information was reported: MYALGIA (non-serious) with onset 26Mar2021 13:00, outcome "recovered" (28Mar2021), described as "muscle aches/ increased muscle aches"; HEADACHE (non-serious) with onset 26Mar2021 13:00, outcome "recovered" (28Mar2021), described as "mild headache/ moderate headache"; SOMNOLENCE (non-serious) with onset 27Mar2021 13:00, outcome "recovered" (28Mar2021), described as "sleepiness"; NAUSEA (non-serious) with onset 27Mar2021 13:00, outcome "recovered" (28Mar2021), described as "nausea"; CHILLS (non-serious) with onset 27Mar2021 13:00, outcome "recovered" (28Mar2021), described as "chills"; NIGHT SWEATS (non-serious) with onset 27Mar2021 13:00, outcome "recovered" (28Mar2021), described as "night sweats." Therapeutic measures were not taken as a result of myalgia, headache, somnolence, nausea, chills, and night sweats.  Additional information: The facility where the most recent COVID-19 vaccine was administered was at the pharmacy or drug store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. There was an onset 24 hours after injection of muscle aches and mild headache. Side effects resolved approximately 42 hours after injection. Forty-eight (48) hours after injection, there was increased muscle aches, moderate headache, sleepiness, nausea, chills, and night sweats. Since the vaccination, the patient had not been tested for COVID-19.  Follow-up attempts are completed. No further information is expected. Information about batch/lot number cannot be obtained.
The client checked in at the facility on 11/21/21 at 12:04 to receive a booster dose of the Moderna COVID19 vaccine.  At approximately 12:06, the RN prepared to administer the vaccine by injecting the client?s right arm with the needle.  When the RN began to push down on the plunger of the syringe, she realized she could not because there was no vaccine in the syringe.  When the RN made this realization, she withdrew the needle from the client?s arm.  The RN informed the client of the error and the client commented that ?she did not feel like she had received anything in her arm.?  The RN apologized to the client, explained she had not been vaccinated, and explained she would need to receive another shot to be properly vaccinated.  The RN stated that the client was not upset and agreed to allow the RN to repeat the process of re-administering the COVID19 Moderna booster shot.  The RN apologized to the client and vaccinated the client in her left arm with a booster shot of COVID19 Moderna vaccine at 12:10. The RN educated the client on both the potential side effects and adverse effects of the vaccine, when to seek medical attention, and ER precautions.  Afterward, the client was escorted to the observation area for a 15-minute observation and no issues were noted.  At approximately 12:30, the RN notified the Lead RN of the administration error.  The RN explained to the Lead RN the details of what had occurred.  The Lead RN explained to the RN that a Lead Nurse should be notified immediately of any vaccine administration errors before proceeding with re-vaccination.  After discussions with the RN, the Lead RN concluded that the client received 0 percent of the COVID19 Moderna vaccine with the first injection conducted by the RN and that re-vaccination was necessary.
Woke up with a golf ball sized bullseye, swollen, red, itchy, sore, and hot to the touch.
Administered Lot#047B21A, but lot#008C21A was logged. Lot#047B21A expired on 5/13/2021.
Immediate soreness at injection site, ongoing achiness. Not extreme, so no treatment. No resolution as of 2/17.  Loss of appetite commenced within 24 hours, and continues. Not extreme, so no treatment, other than eating a normal amount, at normal times, hungry or not. No resolution as of 2/17.  HIVES at injection site appeared 10 days after injection (vax on 2/6, hives on 2/10). Treating with hydrocortisone 1% cream and antihistamines. Call into her PCP. No resolution yet.
12/18 vaccine received in L arm at 1330. At 1900 arm was very sore to touch, and hurt to lift arm. 12/19 0300 L arm very painful to any touch woke up in pain/chills also at this time. 12/19 0700 body aches, most joints hurting quite a bit I would rate 7/10. Chills and body ache persisted throughout day on 12/19 until about 2200. 12/20 0700 Large area (approximately size of a softball) L upper arm tender to touch, reddened, hot to touch. 12/20 1530 area to L arm continues to be hot to touch and grow in size.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In September 2014, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided), at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and on an unknown date the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. The patient was treated by a physician for a blistering vesicular outbreak that was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for the long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient suffered and will continue to suffer significant medical expenses, and pain and suffering and other damages. The outcome of the events were considered to be not recovered. Additional information has been requested.
stinging feeling in arm pit; This is a spontaneous report from a contactable other hcp (reported for herself). A 61-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as SINGLE DOSE, dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date patient experienced stinging feeling in arm pit.Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. patient did not received treatment for the adverse event. Outcome of the event was recovering.   Information on the lot/batch number has been requested.
c/o tingling in tongue within 10 min of receiving vaccine.  EMS on site assessed patient.   10am: Patient reports that she is feeling better and feels OK to go.  Patient reminded that if she still any other reaction to call 911/healthcare provider.
Pt had syncopal episode after vaccination (BP 86/60, HR 74).  Pt stable VS improved (BP 101/77, HR 79, RR 20). Pt stable & released from vaccination site.  Pt has hx of eczema
Developed itchiness in his left arm that occurs at night.  Also reports his arm and the area around the shot feels stiff
On the morning of the 23rd, I noticed hives on my right arm and torso. I met with my prescriber, and I started Prednisone on Morning of the 24th. I am also taking Benadryl. The rash is still ongoing. I was diagnosed as hives with itching all over via medical professional. My doctor recommended also taking OTD Zyrtec and is referring me to an Allergist.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 04-APR-2016 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (lot # L040178, expiration date 18-AUG-2017). This specified lot number vaccine was exposed to temperature excursion three times. The total cumulative excursion time of the first time was 212 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the second time was 24 hours with the highest recorded temperature of 49 Fahrenheit degree. The total cumulative excursion time of the third time was 192 hours with the lowest recorded temperature of 29 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
pt recvd vax; 10aug95 devel fever of 101.2 & approx 30 lesions on body;
The patient was given a Moderna vaccine on 10/22/2021. The pharmacy put a 30-day expiration date on the vial of 11/5/2021. The lot number was not in our EMR system and when brought to the attention of our pharmacy to enter it, they found that it was not in the system because that lot number expired on 10/13/2021.
The patient received the booster dose of COVID-19 on 11/10/21 but had already received the booster dose on 9/30/2021.  The patient received the initial COVID-19 vaccine series on 1/4/2021 and 1/27/2021.   The resident is not currently experiencing any adverse events.   The report is being completed to comply with CDC requirement for Providers to report all COVID-19 vaccine administration errors?even those not associated with an adverse event?to VAERS.
Chest pain, chest wall swelling, pleurisy, and difficulty breathing. Heart felt like it was being torn apart, could not catch my breath.
Pt developed fatigue and numbness in hands and arms, pain in joints, and flu-like symptoms. The annual follow-up states that there are still pain in joints and fatigue. 07/25/2000 09:25 1st attempt to reach pt. Message left on answering machine requesting a call back. 07/26/2000 09:40 2nd attempt to reach pt. Message left on answering machine requestion call back. 07/26/2000 call frompt's wife. His symptoms of joint pain and flu symptoms "come and go". His PCP had diagnosed carpal tunnel syndrome, no Tx. Consent form sent for PCP records.
Complaints of dizzy, nausea, fatigue, knee and ankle joint pain. Had adverse reactions to MMR vaccine on 6/21/06 in the afternoon began to feel very nauseated and dizzy which continued into Thursday in which time she had to leave work and see the doctor and he stated it was probably because of the vaccine. Employee later called on Saturday due to persistent symptoms in which time he prescribed the Compazine. Employee states that she felt much better after that. She also reports symptoms of knee and ankle joint pain and fatigue last Wednesday through today. She states that she is now feeling much better and is able to continue with activities.
sore arm; Headache; Body aches; A spontaneous report was received from a consumer, concerning  a 71 years adult female patient, who received Moderna COVID-19 Vaccine and experienced 2 doses.  The patient's medical history was not provided.  The concomitant products was not provided.  On  22-Jan-2021,prior to the onset of events,the patient received the first dose of  mRNA-1273(lot number: Unknown) and she had taken the second dose on 19-Feb-2021 route of administration is  intramuscular route for COVID-19 infection prophylaxis.  On 30JAN2021 she had a 3 inch square below her injection site which was really red, swollen and tender to touch which gradually spread to her elbow and shoulder. It did not hurt to use her arm. This lasted about a week after which she was fine. Her second dose was administered on Feb 19th. She experienced headache, body aches, no fever.   Treatment includes  Benadryl and Tylenol per doctor recommendation.  Action taken with mRNA-1273 in response to the events were not reported.  The Outcome of the event (Headache,Myalgia,Sorearm) was considered to be not resolved at the time of this report.
Pain at time of inection.  Injection was goven high on shoulder.  Later bruising nodule hot to touch pain radiating through arm and up neck. Numbness in fingers and painful to touch.
Information regarding PREVNAR was received from a healthcare professional regarding a patient who experienced induration. The patient received the second dose on an unspecified date. The patient experienced induration. Outcome unknown. No additional information was available at the time of this report.
This spontaneous report was received from a pharmacist via a company representative and refers to a female patient who was over 65 years old. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with two separate doses of PNEUMOVAX 23 "within one year" (Inappropriate schedule of product administration) for prophylaxis (dose, frequency, route of administration, lot # and expiration date were not reported).
On 5/14/2022, I decided to take an at-home COVID test, as my husband had recently tested positive. My test result was positive, though I didn't have any symptoms. Later that day, I took a PCR test, which also yielded a positive result. The following day, on 5/15/2022, my dog awoke me at about 5 AM, and I noticed that I didn't feel well. I had the symptoms of a slight head cold and a sore throat. As the day went on, I began to have a mild case of chills and a slight fever (99.7 degrees). That day, I consulted with telehealth, and I was prescribed benzonatate and promethazine and they advised me to take Tylenol for pain and Flonase for congestion. I became fatigued and groggy as the day progressed. On Monday, 5/16/2022, the head cold symptoms were slightly diminished, though still present. At the time of this writing, I still have some congestion. The key symptoms I'm currently experiencing are labored breathing and extreme fatigue. If I walk a few steps across the room, I'm winded and exhausted. I've been using a pulse oximeter, and the oxygen levels have been in the range of 89-91. I still some chills, though I'm not feverish.
Positive affects to report. Symptoms of Systemic Sclerosis disease diminished for the 1st time since onset in 2019 - less fatique, clear head (much less "brain fog") and no aura from migraine onset fo; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 10Mar2021 at 13:00 (at the age of 67-years-old) and the patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 31Mar2021 as a single dose for COVID-19 immunisation. Medical history included systemic sclerosis, fatigue, foggy feeling in head and migraine. The patient had allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had received other unspecified medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Mar2021 at 14:00, the patient experienced unexpected beneficial therapeutic response. It was reported that the symptoms of systemic sclerosis disease diminished for the first time since onset in 2019 - less fatigue, clear head (much less brain fog) and no aura from migraine onset for two days. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event unexpected beneficial therapeutic response was recovered on an unknown date in 2021 at the time of this report.  No follow-up attempts are needed. No further information is expected.
Tachycardia, palpitations, elevated blood pressure, feeling faint, nausea, flushing
Shortly after getting his 3rd (booster) shot at Walmart he began feeling unwell, SOB, chilled.  His wife states he had mild reaction to the first with typical fever, chills, aches, some vomiting.  The second shot was much worse with SOB and confusion.  Now, the booster shot has resulted in hospitalization within 24 hours with PE, troponin elevation, reduced EF 20%, pneumonitis with respiratory failure on non-invasive vent support.
Unknown if s/s related to vaccine. Was dx with hypothyroidism in May 2021. Vague s/s progressing up to prominent symptoms. Dx managed with rx
patient called after hours RN triage line with complaint of chest pain.  Was referred to ER- work up unremarkable and patient send home without intervention or medication
Patient received a pediatric dose (0.2 mL) of Pfizer vaccine instead of regular dose (0.3 mL). Once error was discovered, patient was asked to return to the pharmacy. Upon return, patient was administered 0.2 ml of regular dose Pfizer vaccine. This action ensures that the patient received an equivalent dose of the vaccine as one regular dose.
This spontaneous report as received from a certified medical assistant refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history and concurrent conditions was provided. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL 9, lot # L016429, expiration date: August 2017, (exact dates, injection site and route of administration were not reported). There were no concomitant medications reported. It was stated that the vaccines were exposed to the temperature of 30 degrees Fahrenheit for 20 hours and to the temperature of 53 degrees Fahrenheit for 19 hours. No previous temperature excursion was reported. No adverse effects were reported. No PQC (product quality complaint) was involved. Follow-up information received on 29-MAR-2016 indicated that all telephone attempts to obtain follow-up information had been unsuccessful. Follow up information has been received on 01-APR-2016 from the unspecified reporter concerning a patient of unknown age and gender who on 20-NOV-2015 was vaccinated with improperly stored dose of GARDASIL 9, lot # K016966, expiration date: May 2017. The reporter also stated that thermometer was malfunctioning during the excursion and clarified that no COMVAX (as previously reported) only GARDASIL 9 was involved. This is one of several reports received from the same reporter. Additional information is not expected as all required information has been received. Reporters, patient details, suspect details, event details and narrative were updated.